• 1
    Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol. 2006; 19: 655-668.
  • 2
    Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2: 457-470.
  • 3
    Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 3793-3803.
  • 4
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 2453-2463.
  • 5
    Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 3262-3269.
  • 6
    Crawford LM Jr. From the Food and Drug Administration. JAMA. 2002; 287: 1640.
  • 7
    Kaminski MS, Press OW, Lister TA, Valente NK, Kroll S, Tidmarsh G. Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience [abstract]. Blood. 1999; 88. Abstract.
  • 8
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
  • 9
    Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 1263-1270.
  • 10
    Emmanouilides CE, Witzig TE, Molina A, et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 2392.
  • 11
    Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Res. Network J Clin Oncol. 2003; 21: 1746-1751.
  • 12
    Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002; 69: 129-134.
  • 13
    O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 2165-2170.
  • 14
    Emmanouilides C, Murray JL, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalln) radiolmmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-Cell non-Hodgkin's lymphoma: results with second-line therapy [abstract]. Blood. 2003; 102: 306b. Abstract 4949.